Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia

A retrospective case series review was conducted to determine the pre-operative role and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring vitrectomy. The study involved twenty conse...

Full description

Bibliographic Details
Main Authors: Bastion MLC, Siti Aishah S, Aida Zairani MZ, Barkeh HJ
Format: Article
Language:English
Published: Penerbit UKM 2010
Online Access:http://journalarticle.ukm.my/2086/
http://journalarticle.ukm.my/2086/1/08MS090_4144.pdf
_version_ 1848809754032340992
author Bastion MLC,
Siti Aishah S,
Aida Zairani MZ,
Barkeh HJ,
author_facet Bastion MLC,
Siti Aishah S,
Aida Zairani MZ,
Barkeh HJ,
author_sort Bastion MLC,
building UKM Institutional Repository
collection Online Access
description A retrospective case series review was conducted to determine the pre-operative role and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring vitrectomy. The study involved twenty consecutive eyes of sixteen patients (age range: 46-72 years; mean 57.5 years) which received intravitreal injection of 0.5 - 1 mg of ranibizumab 3 to 8 days (mean 4.4 days) prior to vitrectomy for diabetic retinopathy. There were no local or systemic post-injection complications. Indications for vitrectomy were retinal detachment (RD) [n=11; 3 combined tractional (TRD) - rhegmatogenous RD (RRD), 8 TRD], TRD with vitreous haemorrhage (VH) (n=3) ,VH (n=8) and vitreomacular traction syndrome (n=1). Inclusion criteria include all consecutive eyes of diabetic patients requiring vitrectomy receiving a first pre-operative injection of anti- VEGF. Pre-operative visual acuity (VA) ranged from 6/36 to light perception. All eyes had minimal to moderate intraoperative bleeding. Post-operative VH in eyes without tamponade or gas tamponade was nil (n=1), mild (n=13) or moderate (n=1). Silicone filled eyes had nil (n=1), moderate (n=3) or severe haemorrhages (n=1). Post-operative VA was unchanged (n=2) (10%), improved (n = 14) (70%) or worsened (n=4). VA was 2/60 or better (n=15) to no light perception (n=1). Two eyes achieved 6/12 or better vision (10%). Ten eyes (50%) had 6/36 or better vision. In conclusion, pre-operative intravitreal ranibizumab is safe and useful in diabetic vitrectomy and appears to help with perioperative bleeding leading to improvement in vision.
first_indexed 2025-11-14T23:19:38Z
format Article
id oai:generic.eprints.org:2086
institution Universiti Kebangasaan Malaysia
institution_category Local University
language English
last_indexed 2025-11-14T23:19:38Z
publishDate 2010
publisher Penerbit UKM
recordtype eprints
repository_type Digital Repository
spelling oai:generic.eprints.org:20862016-12-14T06:30:51Z http://journalarticle.ukm.my/2086/ Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia Bastion MLC, Siti Aishah S, Aida Zairani MZ, Barkeh HJ, A retrospective case series review was conducted to determine the pre-operative role and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring vitrectomy. The study involved twenty consecutive eyes of sixteen patients (age range: 46-72 years; mean 57.5 years) which received intravitreal injection of 0.5 - 1 mg of ranibizumab 3 to 8 days (mean 4.4 days) prior to vitrectomy for diabetic retinopathy. There were no local or systemic post-injection complications. Indications for vitrectomy were retinal detachment (RD) [n=11; 3 combined tractional (TRD) - rhegmatogenous RD (RRD), 8 TRD], TRD with vitreous haemorrhage (VH) (n=3) ,VH (n=8) and vitreomacular traction syndrome (n=1). Inclusion criteria include all consecutive eyes of diabetic patients requiring vitrectomy receiving a first pre-operative injection of anti- VEGF. Pre-operative visual acuity (VA) ranged from 6/36 to light perception. All eyes had minimal to moderate intraoperative bleeding. Post-operative VH in eyes without tamponade or gas tamponade was nil (n=1), mild (n=13) or moderate (n=1). Silicone filled eyes had nil (n=1), moderate (n=3) or severe haemorrhages (n=1). Post-operative VA was unchanged (n=2) (10%), improved (n = 14) (70%) or worsened (n=4). VA was 2/60 or better (n=15) to no light perception (n=1). Two eyes achieved 6/12 or better vision (10%). Ten eyes (50%) had 6/36 or better vision. In conclusion, pre-operative intravitreal ranibizumab is safe and useful in diabetic vitrectomy and appears to help with perioperative bleeding leading to improvement in vision. Penerbit UKM 2010 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/2086/1/08MS090_4144.pdf Bastion MLC, and Siti Aishah S, and Aida Zairani MZ, and Barkeh HJ, (2010) Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia. Medicine & Health, 5 (2). pp. 93-102. ISSN 1823-2140 http://www.ppukm.ukm.my/ukmmcjournal/index.php
spellingShingle Bastion MLC,
Siti Aishah S,
Aida Zairani MZ,
Barkeh HJ,
Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_full Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_fullStr Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_full_unstemmed Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_short Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_sort retrospective review of the adjunctive use of pre- operative ranibizumab “lucentistm” in the surgical management of diabetic retinopathy in a tertiary referral hospital in malaysia
url http://journalarticle.ukm.my/2086/
http://journalarticle.ukm.my/2086/
http://journalarticle.ukm.my/2086/1/08MS090_4144.pdf